<article article-type="brief-report" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Liver Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Liver Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">2074</journal-id><journal-id journal-id-type="pmc-domain">lic</journal-id><journal-id journal-id-type="publisher-id">LIC</journal-id><journal-title-group><journal-title>Liver Cancer</journal-title></journal-title-group><issn pub-type="ppub">2235-1795</issn><issn pub-type="epub">1664-5553</issn><publisher><publisher-name>Karger Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12830029</article-id><article-id pub-id-type="pmcid-ver">PMC12830029.1</article-id><article-id pub-id-type="pmcaid">12830029</article-id><article-id pub-id-type="pmcaiid">12830029</article-id><article-id pub-id-type="pmid">41585428</article-id><article-id pub-id-type="doi">10.1159/000549955</article-id><article-id pub-id-type="publisher-id">549955</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis</article-title><alt-title alt-title-type="short">Safety Results from the SIERRA Study in Unresectable Hepatocellular Carcinoma</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="false" contrib-id-type="relnr">2810621</contrib-id><name name-style="western"><surname>Chan</surname><given-names initials="SL">Stephen Lam</given-names></name><xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810622</contrib-id><name name-style="western"><surname>Kudo</surname><given-names initials="M">Masatoshi</given-names></name><xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810623</contrib-id><name name-style="western"><surname>Sangro</surname><given-names initials="B">Bruno</given-names></name><xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810624</contrib-id><name name-style="western"><surname>Kelley</surname><given-names initials="RK">Robin Kate</given-names></name><xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810625</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="JH">Jee Hyun</given-names></name><xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810626</contrib-id><name name-style="western"><surname>Pham</surname><given-names initials="B">Binh</given-names></name><xref ref-type="aff" rid="aff6">
<sup>f</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810627</contrib-id><name name-style="western"><surname>Hong</surname><given-names initials="JY">Jung Yong</given-names></name><xref ref-type="aff" rid="aff7">
<sup>g</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810628</contrib-id><name name-style="western"><surname>Waldschmidt</surname><given-names initials="DT">Dirk-Thomas</given-names></name><xref ref-type="aff" rid="aff8">
<sup>h</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810629</contrib-id><name name-style="western"><surname>Marino</surname><given-names initials="D">Donatella</given-names></name><xref ref-type="aff" rid="aff9">
<sup>i</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810630</contrib-id><name name-style="western"><surname>Joycelyn Lee</surname><given-names initials="JX">Jie Xin</given-names></name><xref ref-type="aff" rid="aff10">
<sup>j</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810631</contrib-id><name name-style="western"><surname>Gerolami</surname><given-names initials="R">René</given-names></name><xref ref-type="aff" rid="aff11">
<sup>k</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810632</contrib-id><name name-style="western"><surname>Burgoyne</surname><given-names initials="AM">Adam M.</given-names></name><xref ref-type="aff" rid="aff12">
<sup>l</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810633</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="Q">Qiao</given-names></name><xref ref-type="aff" rid="aff13">
<sup>m</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810634</contrib-id><name name-style="western"><surname>Nakamura</surname><given-names initials="H">Hitomi</given-names></name><xref ref-type="aff" rid="aff14">
<sup>n</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810635</contrib-id><name name-style="western"><surname>Sun</surname><given-names initials="P">Peng</given-names></name><xref ref-type="aff" rid="aff15">
<sup>o</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810636</contrib-id><name name-style="western"><surname>Baur</surname><given-names initials="B">Boris</given-names></name><xref ref-type="aff" rid="aff15">
<sup>o</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="relnr">2810637</contrib-id><name name-style="western"><surname>Rimassa</surname><given-names initials="L">Lorenza</given-names></name><xref ref-type="aff" rid="aff16">
<sup>p</sup>
</xref><xref ref-type="aff" rid="aff17">
<sup>q</sup>
</xref></contrib><aff id="aff1">
<label>a</label>State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, <city>Hong Kong</city>, <country>Hong Kong SAR</country></aff><aff id="aff2">
<label>b</label>Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, <city>Osaka</city>, <country>Japan</country></aff><aff id="aff3">
<label>c</label>Liver Unit and HPB Oncology Area, Clínica Universidad de Navarra and CIBEREHD, <city>Pamplona</city>, <country>Spain</country></aff><aff id="aff4">
<label>d</label>Helen Diller Family Comprehensive Cancer Center, University of California, <city>San Francisco</city>, <state>CA</state>, <country>USA</country></aff><aff id="aff5">
<label>e</label>Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, <city>Seongnam</city>, <country>Republic of Korea</country></aff><aff id="aff6">
<label>f</label>Abdominal Department 1 and Robotic Surgery, Vietnam National Cancer Hospital, <city>Hanoi</city>, <country>Vietnam</country></aff><aff id="aff7">
<label>g</label>Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, <city>Seoul</city>, <country>Republic of Korea</country></aff><aff id="aff8">
<label>h</label>Department of Gastroenterology and Hepatology, University Hospital Cologne, <city>Cologne</city>, <country>Germany</country></aff><aff id="aff9">
<label>i</label>Department of Oncology, Ordine Mauriziano Hospital, <city>Turin</city>, <country>Italy</country></aff><aff id="aff10">
<label>j</label>Division of Medical Oncology, National Cancer Centre, <city>Singapore</city>, <country>Singapore</country></aff><aff id="aff11">
<label>k</label>Assistance Publique-Hôpitaux de Marseille, Université Aix-Marseille, <city>Marseille</city>, <country>France</country></aff><aff id="aff12">
<label>l</label>Division of Hematology-Oncology, Department of Medicine, UC San Diego, <city>La Jolla</city>, <state>CA</state>, <country>USA</country></aff><aff id="aff13">
<label>m</label>Oncology Biometrics, AstraZeneca, <city>Mississauga</city>, <state>ON</state>, <country>Canada</country></aff><aff id="aff14">
<label>n</label>Global Medical Affairs, AstraZeneca, <city>Cambridge</city>, <country>UK</country></aff><aff id="aff15">
<label>o</label>Global Medical Affairs, AstraZeneca, <city>Gaithersburg</city>, <state>MD</state>, <country>USA</country></aff><aff id="aff16">
<label>p</label>Department of Biomedical Sciences, Humanitas University, <city>Milan</city>, <country>Italy</country></aff><aff id="aff17">
<label>q</label>Humanitas Cancer Center, IRCCS Humanitas Research Hospital, <city>Milan</city>, <country>Italy</country></aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Stephen Lam Chan, <email>chanlam_stephen@cuhk.edu.hk</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>12</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">486653</issue-id><history><date date-type="received"><day>26</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>24</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-26 15:25:12.620"><day>26</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2025 The Author(s). Published by S. Karger AG, Basel</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref content-type="ccbynclicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (<ext-link ext-link-type="uri" xlink:href="https://karger.com/Services/OpenAccessLicense" xmlns:xlink="http://www.w3.org/1999/xlink">https://karger.com/Services/OpenAccessLicense</ext-link>). Usage and distribution for commercial purposes requires written permission.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="lic-2025-0000-0000-549955.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>Subgroups of people with unresectable hepatocellular carcinoma (uHCC) are often excluded from clinical trials due to adverse prognostic factors. The SIERRA (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT05883644" xmlns:xlink="http://www.w3.org/1999/xlink">NCT05883644</ext-link>) study assesses the efficacy and safety of STRIDE (Single Tremelimumab Regular Interval Durvalumab) in clinically relevant subgroups of uHCC with poorer prognosis, including participants with more decompensated hepatic function, worse performance status, or more advanced disease than the HIMALAYA (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03298451" xmlns:xlink="http://www.w3.org/1999/xlink">NCT03298451</ext-link>) study.</p></sec><sec><title>Methods</title><p>SIERRA is a phase 3b, single-arm, multicenter study that enrolled participants with uHCC with: Child-Pugh (CP) class of B7 or B8 with Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1, without main trunk portal vein thrombosis (PVT) (CP B7/B8 cohort); CP class A with ECOG PS 2, without main trunk PVT (ECOG PS 2 cohort); or CP class A with ECOG PS 0–1 with evidence of chronic main trunk PVT (Vp4 cohort). Participants received STRIDE (tremelimumab 300 mg plus durvalumab 1,500 mg once followed by durvalumab 1,500 mg every 4 weeks). This preplanned early safety analysis occurred once ∼60 participants had been followed for ≥6 months (data cutoff: September 27, 2024). Co-primary endpoints are incidence of grade 3/4 adverse events (AEs) possibly related to study treatment (PRAEs) within 6 months of treatment initiation and objective response rate. The study is ongoing.</p></sec><sec><title>Results</title><p>This analysis included 98 participants (CP B7/B8 cohort, <italic toggle="yes">n</italic> = 35; ECOG PS 2 cohort, <italic toggle="yes">n</italic> = 44; Vp4 cohort, <italic toggle="yes">n</italic> = 19). Median (Q1–Q3) number of cycles of durvalumab was 4.0 (2.0–8.0). Incidence of grade 3/4 PRAEs occurring within 6 months of treatment was 19.4% (95% confidence interval, 12.1–28.6) overall. Incidence of serious AEs was 32.7%. PRAEs, leading to death, occurred in 2.0% of participants.</p></sec><sec><title>Conclusion</title><p>The safety profile of STRIDE was manageable and consistent with the HIMALAYA study in participants with poorer prognosis than in HIMALAYA.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Liver neoplasm</kwd><kwd>Immunotherapy</kwd><kwd>Combination</kwd><kwd>Safety</kwd><kwd>Vascular invasion</kwd><kwd>Cirrhosis</kwd></kwd-group><funding-group><funding-statement>This study was funded by AstraZeneca. AstraZeneca sponsored the trial, provided the trial drugs, and collaborated with the Steering Committee on the trial design and data collection, analysis, and interpretation. The manuscript was prepared and approved by all authors, with medical writing support funded by the sponsor. The sponsor reviewed and approved for submission the final draft of the manuscript to ensure accuracy of references to AstraZeneca products and clinical studies, guard against disclosure of confidential information, and check that information relevant to pending patents was handled appropriately.</funding-statement></funding-group><counts><table-count count="3"/><ref-count count="28"/><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>accessibilitySummary</meta-name><meta-value>WCAG 2.1 Level AA</meta-value></custom-meta><custom-meta><meta-name>accessibility-pdf-ua-compliance</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="introduction"><title>Introduction</title><p>Liver cancer is the sixth most common cancer and the third leading cause of cancer deaths worldwide [<xref ref-type="bibr" rid="B1">1</xref>]. Hepatocellular carcinoma (HCC) is commonly diagnosed at or progresses to an advanced, unresectable stage, for which surgery is not an option and systemic therapy is the recommended treatment [<xref ref-type="bibr" rid="B2">2</xref>–<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Until recently, first-line treatment for unresectable HCC (uHCC) was limited to multikinase inhibitors such as lenvatinib and sorafenib [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. In recent years, immune checkpoint inhibitor-based therapies including STRIDE (Single Tremelimumab [anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)] Regular Interval Durvalumab [anti-programmed cell death ligand-1 (PD-L1)]), atezolizumab (anti-PD-L1) plus bevacizumab (anti-vascular endothelial growth factor [VEGF]), camrelizumab (anti-PD-L1) plus rivoceranib (anti-VEGF) and ipilimumab (anti-CTLA-4) plus nivolumab (anti-programmed cell death-1 [PD-1]) have significantly improved outcomes versus sorafenib or lenvatinib, leading to several approvals as first-line treatment options for uHCC [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B6">6</xref>–<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Historically, individuals with certain adverse prognostic factors have been excluded from HCC clinical trials, including those with decompensated hepatic function (Child-Pugh [CP] B or C), main portal vein thrombosis (PVT), or an Eastern Cooperative Oncology Group performance status (ECOG PS) greater than 1 [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B11">11</xref>]. As a result, making treatment recommendations for this population is challenging due to the lack of clinical trial data. As the STRIDE regimen does not utilize multikinase or VEGF inhibitors, it may be a suitable option for those with more advanced disease who are at increased risk of side effects with multikinase inhibitor use, or those at increased risk of bleeding who are poor candidates for anti-VEGF therapies [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>In the phase 3 HIMALAYA study (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03298451" xmlns:xlink="http://www.w3.org/1999/xlink">NCT03298451</ext-link>), STRIDE significantly improved overall survival versus sorafenib in the primary analysis of the global cohort, with manageable safety and low incidence of hemorrhage adverse events (AEs) with STRIDE (11.3%) [<xref ref-type="bibr" rid="B7">7</xref>]. The overall survival benefit with STRIDE versus sorafenib persisted with 4 and 5 years of follow-up [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>]. Based on results from the HIMALAYA study, the STRIDE regimen has been approved across the world for the treatment of adults with uHCC, including Europe, Japan, Korea, Taiwan, and the USA [<xref ref-type="bibr" rid="B14">14</xref>–<xref ref-type="bibr" rid="B20">20</xref>]. The HIMALAYA study, like other pivotal phase 3 studies in uHCC, included participants with well-preserved liver function (CP class A) and a good functional status (ECOG PS 0–1), which accounts for only 35–40% of people with uHCC [<xref ref-type="bibr" rid="B7">7</xref>]. Furthermore, the HIMALAYA study excluded participants with main trunk PVT, which is associated with a less favorable prognosis [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The efficacy and safety of ICI-based therapies is largely undocumented in clinical trials for those with poor prognostic factors such as decompensated liver function (CP class B), poor functional status (ECOG PS 2), or main trunk PVT; therefore, there is an urgent, unmet medical need for clinical data demonstrating the safety of ICI-based therapies in these populations. In the phase 1/2 CheckMate 040 study, nivolumab demonstrated clinical activity and acceptable safety in participants with CP B HCC, suggesting that ICI-based therapies may be tolerated in this population [<xref ref-type="bibr" rid="B21">21</xref>]. However, additional evidence supporting the use of ICI-based therapies in broader populations is usually gained from real-world studies, which are limited by their retrospective nature [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>].</p><p>SIERRA is a phase 3b, single-arm, multicenter study assessing the safety and efficacy of STRIDE in an expanded population of participants with uHCC who have poor prognostic factors such as decompensated liver function, poor functional status, or main trunk PVT, reflecting a real-world population that has historically been excluded from clinical trials, such as HIMALAYA. The SIERRA study aims to address the unmet need for new treatment options in difficult-to-treat populations and to address safety concerns associated with treating a more fragile population. Here, we report early safety findings from the SIERRA study. Efficacy will be reported at the subsequent primary analysis.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study Design and Participants</title><p>SIERRA (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT05883644" xmlns:xlink="http://www.w3.org/1999/xlink">NCT05883644</ext-link>) is a phase 3b, single-arm, multicenter study that enrolled participants with histologically confirmed uHCC, who have Barcelona Clinic Liver Cancer (BCLC) stage B or C, and can be categorized as one of the following groups: CP class of B7 or B8 with ECOG PS 0–1, without main trunk PVT (CP B7/B8 cohort); CP class A with ECOG PS 2, without main trunk PVT (ECOG PS 2 cohort); or CP class A with ECOG PS 0–1 with evidence of chronic main trunk PVT, defined as presence of thrombus for at least 4 weeks or visible collaterals on imaging (assessed locally by the investigator; Vp4 cohort). Eligible participants must not have received prior systemic therapy for HCC and must have been deemed ineligible for locoregional therapy per investigator assessment. Key exclusion criteria included evidence of acute main trunk PVT or active or recent (within the past 6 months) gastrointestinal bleeding.</p><p>All participants received STRIDE (one single priming dose of 300 mg tremelimumab plus 1,500 mg durvalumab at day 1 [week 0], followed by durvalumab 1,500 mg monotherapy every 4 weeks starting at week 4) until clinical progression, confirmed radiological progression (per Response Evaluation Criteria In Solid Tumors v1.1 [RECIST 1.1]), unacceptable toxicity, withdrawal of consent, or any discontinuation criteria were met.</p></sec><sec id="s2-2"><title>Endpoints and Assessments</title><p>The co-primary endpoints are the incidence of grade 3 or 4 AEs possibly related to study treatment (PRAEs) within 6 months after initiation of STRIDE and investigator-assessed (RECIST 1.1) objective response rate (ORR). PRAEs were defined as an AE where the investigator answered “yes” to the question “Do you consider that there is a reasonable possibility that the event may have been caused by the investigational product?”</p><p>Secondary endpoints include overall survival, progression-free survival, disease control rate, duration of response, duration of treatment, safety, and health-related quality of life. This preplanned early safety analysis was performed when approximately 60 participants had been followed for at least 6 months. Participant demographics, disease characteristics, and safety outcomes were assessed in the safety analysis set, which included all participants who received ≥1 dose of STRIDE by the data cutoff (September 27, 2024). Safety outcomes assessed included grade 3 or 4 PRAEs (95% confidence interval) occurring within 6 months of treatment initiation (co-primary endpoint), incidence of AEs and PRAEs, serious AEs (SAEs) and serious PRAEs, AEs and PRAEs leading to discontinuation, AEs and PRAEs leading to death, immune-mediated AEs (imAEs), and hemorrhagic AEs. Efficacies, including ORR, were immature at the time of data cutoff. The study is ongoing to assess the primary and secondary endpoints.</p></sec><sec id="s2-3"><title>Trial Oversight</title><p>The SIERRA study was conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation Guideline for Good Clinical Practice, applicable regulatory requirements, and the AstraZeneca Bioethics Policy. Written, informed consent was obtained from participants or their legal representatives before participation.</p></sec><sec id="s2-4"><title>Statistical Analysis</title><p>No formal sample size calculation was done; however, the sample size was estimated based on the incidence of grade 3 or 4 treatment-related AEs (25.8%) and the ORR (20.1%) from the STRIDE arm of the HIMALAYA study, with treatment-related AEs expected to be higher and ORR expected to be lower in SIERRA due to the differences in population [<xref ref-type="bibr" rid="B7">7</xref>]. Based on precision estimates using the binomial (Clopper-Pearson) exact method, a sample size of 110 participants was estimated to provide an adequate level of confidence in the incidence of grade 3 or 4 PRAEs and ORR.</p><p>In this early safety analysis, all baseline characteristics and endpoints were assessed for all participants and in the CP B7/B8, ECOG PS 2, and Vp4 cohorts. Baseline characteristics were summarized descriptively. Percentages were calculated from the number of participants overall and in each respective cohort. The incidence of grade 3 or 4 PRAEs within 6 months after initiation of STRIDE was summarized by frequency counts and 95% confidence interval based on the binomial exact method (Clopper-Pearson). Safety data are summarized descriptively.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Study Population and Treatment</title><p>At the data cutoff, 166 participants had been screened and 98 participants had received ≥1 dose of any study treatment (CP B7/B8 cohort, <italic toggle="yes">n</italic> = 35; ECOG PS 2 cohort, <italic toggle="yes">n</italic> = 44; Vp4 cohort, <italic toggle="yes">n</italic> = 19; online suppl. Fig. 1; for all online suppl. material, see <ext-link ext-link-type="doi" xlink:href="10.1159/000549955" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1159/000549955</ext-link>). In total, 65/98 (66.3%) participants were ongoing in the study, including 50/98 (51.0%) participants who were still receiving study treatment. The median (range) duration of safety follow-up was 5.2 (0.1–13.4) months overall, 2.4 (0.1–10.7) months for participants in the CP B7/B8 cohort, 6.9 (1.0–13.4) months for participants in the ECOG PS 2 cohort, and 5.0 (0.6–10.8) months for participants in the Vp4 cohort.</p><p>The median (range) age was 70.0 (37–89) years overall, 69.0 (47–88) years in the CP B7/B8 cohort, 74.0 (41–89) years in the ECOG PS 2 cohort, and 65.0 (37–85) years in the Vp4 cohort (<xref ref-type="table" rid="T1">Table 1</xref>). In total, 39/98 (39.8%) participants had hepatitis B virus, 15/98 (15.3%) participants had hepatitis C virus, and 42/98 (42.9%) participants had another (nonviral) etiology at screening (<xref ref-type="table" rid="T1">Table 1</xref>). Baseline demographics were generally consistent across the three cohorts (<xref ref-type="table" rid="T1">Table 1</xref>). However, some clinical characteristics such as albumin-bilirubin grade and BCLC stage differed among cohorts, reflective of the differing inclusion criteria for each cohort in regard to CP score, ECOG PS, and main trunk PVT presence (<xref ref-type="table" rid="T1">Table 1</xref>). A larger proportion of participants in the CP B7/B8 and ECOG PS 2 cohorts had received prior anticancer therapy compared with the Vp4 cohort (online suppl. Table 1).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline demographic and disease characteristics at screening in the safety analysis set</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">​</th><th colspan="1" rowspan="1">CP B7/B8 cohort, <italic toggle="yes">n</italic> = 35</th><th colspan="1" rowspan="1">ECOG PS 2 cohort, <italic toggle="yes">n</italic> = 44</th><th colspan="1" rowspan="1">Vp4 cohort, <italic toggle="yes">n</italic> = 19</th><th colspan="1" rowspan="1">Overall, <italic toggle="yes">N</italic> = 98</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age, median (range), years</td><td colspan="1" rowspan="1">69.0 (47–88)</td><td colspan="1" rowspan="1">74.0 (41–89)</td><td colspan="1" rowspan="1">65.0 (37–85)</td><td colspan="1" rowspan="1">70.0 (37–89)</td></tr><tr><td colspan="5" rowspan="1">Sex, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> Male</td><td colspan="1" rowspan="1">29 (82.9)</td><td colspan="1" rowspan="1">39 (88.6)</td><td colspan="1" rowspan="1">17 (89.5)</td><td colspan="1" rowspan="1">85 (86.7)</td></tr><tr><td colspan="1" rowspan="1"> Female</td><td colspan="1" rowspan="1">6 (17.1)</td><td colspan="1" rowspan="1">5 (11.4)</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">13 (13.3)</td></tr><tr><td colspan="5" rowspan="1">Race, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> White</td><td colspan="1" rowspan="1">10 (28.6)</td><td colspan="1" rowspan="1">17 (38.6)</td><td colspan="1" rowspan="1">13 (68.4)</td><td colspan="1" rowspan="1">40 (40.8)</td></tr><tr><td colspan="1" rowspan="1"> Asian</td><td colspan="1" rowspan="1">16 (45.7)</td><td colspan="1" rowspan="1">25 (56.8)</td><td colspan="1" rowspan="1">6 (31.6)</td><td colspan="1" rowspan="1">47 (48.0)</td></tr><tr><td colspan="1" rowspan="1"> Not reported<sup>a</sup></td><td colspan="1" rowspan="1">9 (25.7)</td><td colspan="1" rowspan="1">2 (4.5)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">11 (11.2)</td></tr><tr><td colspan="5" rowspan="1">ALBI grade, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> Grade 1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">25 (56.8)</td><td colspan="1" rowspan="1">6 (31.6)</td><td colspan="1" rowspan="1">31 (31.6)</td></tr><tr><td colspan="1" rowspan="1"> Grade 2</td><td colspan="1" rowspan="1">31 (88.6)</td><td colspan="1" rowspan="1">19 (43.2)</td><td colspan="1" rowspan="1">13 (68.4)</td><td colspan="1" rowspan="1">63 (64.3)</td></tr><tr><td colspan="1" rowspan="1"> Grade 3</td><td colspan="1" rowspan="1">4 (11.4)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4 (4.1)</td></tr><tr><td colspan="5" rowspan="1">Child-Pugh classification, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> Class A</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">44 (100.0)</td><td colspan="1" rowspan="1">19 (100.0)</td><td colspan="1" rowspan="1">63 (64.3)</td></tr><tr><td colspan="1" rowspan="1"> Class B</td><td colspan="1" rowspan="1">35 (100.0)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">35 (35.7)</td></tr><tr><td colspan="5" rowspan="1">BCLC stage, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> B</td><td colspan="1" rowspan="1">15 (42.9)</td><td colspan="1" rowspan="1">7 (15.9)</td><td colspan="1" rowspan="1">3 (15.8)</td><td colspan="1" rowspan="1">25 (25.5)</td></tr><tr><td colspan="1" rowspan="1"> C</td><td colspan="1" rowspan="1">20 (57.1)</td><td colspan="1" rowspan="1">37 (84.1)</td><td colspan="1" rowspan="1">16 (84.2)</td><td colspan="1" rowspan="1">73 (74.5)</td></tr><tr><td colspan="5" rowspan="1">Alpha-fetoprotein, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> &lt;400 ng/mL</td><td colspan="1" rowspan="1">24 (68.6)</td><td colspan="1" rowspan="1">30 (68.2)</td><td colspan="1" rowspan="1">10 (52.6)</td><td colspan="1" rowspan="1">64 (65.3)</td></tr><tr><td colspan="1" rowspan="1"> ≥400 ng/mL</td><td colspan="1" rowspan="1">11 (31.4)</td><td colspan="1" rowspan="1">14 (31.8)</td><td colspan="1" rowspan="1">9 (47.4)</td><td colspan="1" rowspan="1">34 (34.7)</td></tr><tr><td colspan="5" rowspan="1">Tumor grade, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> G1</td><td colspan="1" rowspan="1">7 (20.0)</td><td colspan="1" rowspan="1">7 (15.9)</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">16 (16.3)</td></tr><tr><td colspan="1" rowspan="1"> G2</td><td colspan="1" rowspan="1">12 (34.3)</td><td colspan="1" rowspan="1">14 (31.8)</td><td colspan="1" rowspan="1">7 (36.8)</td><td colspan="1" rowspan="1">33 (33.7)</td></tr><tr><td colspan="1" rowspan="1"> G3</td><td colspan="1" rowspan="1">7 (20.0)</td><td colspan="1" rowspan="1">3 (6.8)</td><td colspan="1" rowspan="1">4 (21.1)</td><td colspan="1" rowspan="1">14 (14.3)</td></tr><tr><td colspan="1" rowspan="1"> GX</td><td colspan="1" rowspan="1">9 (25.7)</td><td colspan="1" rowspan="1">20 (45.5)</td><td colspan="1" rowspan="1">6 (31.6)</td><td colspan="1" rowspan="1">35 (35.7)</td></tr><tr><td colspan="5" rowspan="1">Primary tumor, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> T1</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">2 (4.5)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">3 (3.1)</td></tr><tr><td colspan="1" rowspan="1"> T1a</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">1 (1.0)</td></tr><tr><td colspan="1" rowspan="1"> T1b</td><td colspan="1" rowspan="1">2 (5.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (2.0)</td></tr><tr><td colspan="1" rowspan="1"> T2</td><td colspan="1" rowspan="1">9 (25.7)</td><td colspan="1" rowspan="1">11 (25.0)</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">21 (21.4)</td></tr><tr><td colspan="1" rowspan="1"> T3</td><td colspan="1" rowspan="1">9 (25.7)</td><td colspan="1" rowspan="1">17 (38.6)</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">28 (28.6)</td></tr><tr><td colspan="1" rowspan="1"> T4</td><td colspan="1" rowspan="1">9 (25.7)</td><td colspan="1" rowspan="1">9 (20.5)</td><td colspan="1" rowspan="1">14 (73.7)</td><td colspan="1" rowspan="1">32 (32.7)</td></tr><tr><td colspan="1" rowspan="1"> TX</td><td colspan="1" rowspan="1">4 (11.4)</td><td colspan="1" rowspan="1">4 (9.1)</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">9 (9.2)</td></tr><tr><td colspan="1" rowspan="1"> Unknown</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (1.0)</td></tr><tr><td colspan="1" rowspan="1"> Missing</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (1.0)</td></tr><tr><td colspan="5" rowspan="1">Regional lymph nodes, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> N0</td><td colspan="1" rowspan="1">22 (62.9)</td><td colspan="1" rowspan="1">34 (77.3)</td><td colspan="1" rowspan="1">12 (63.2)</td><td colspan="1" rowspan="1">68 (69.4)</td></tr><tr><td colspan="1" rowspan="1"> N1</td><td colspan="1" rowspan="1">6 (17.1)</td><td colspan="1" rowspan="1">2 (4.5)</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">10 (10.2)</td></tr><tr><td colspan="1" rowspan="1"> NX</td><td colspan="1" rowspan="1">6 (17.1)</td><td colspan="1" rowspan="1">8 (18.2)</td><td colspan="1" rowspan="1">5 (26.3)</td><td colspan="1" rowspan="1">19 (19.4)</td></tr><tr><td colspan="1" rowspan="1"> Missing</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (1.0)</td></tr><tr><td colspan="5" rowspan="1">Primary tumor location, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> Liver</td><td colspan="1" rowspan="1">33 (94.3)</td><td colspan="1" rowspan="1">44 (100.0)</td><td colspan="1" rowspan="1">18 (94.7)</td><td colspan="1" rowspan="1">95 (96.9)</td></tr><tr><td colspan="1" rowspan="1"> Other</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">2 (2.0)</td></tr><tr><td colspan="1" rowspan="1"> Missing</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (1.0)</td></tr><tr><td colspan="5" rowspan="1">Distant metastases, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> M0</td><td colspan="1" rowspan="1">27 (77.1)</td><td colspan="1" rowspan="1">28 (63.6)</td><td colspan="1" rowspan="1">13 (68.4)</td><td colspan="1" rowspan="1">68 (69.4)</td></tr><tr><td colspan="1" rowspan="1"> M1</td><td colspan="1" rowspan="1">8 (22.9)</td><td colspan="1" rowspan="1">16 (36.4)</td><td colspan="1" rowspan="1">6 (31.6)</td><td colspan="1" rowspan="1">30 (30.6)</td></tr><tr><td colspan="5" rowspan="1">Virology status, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> Hepatitis B virus</td><td colspan="1" rowspan="1">13 (37.1)</td><td colspan="1" rowspan="1">17 (38.6)</td><td colspan="1" rowspan="1">9 (47.4)</td><td colspan="1" rowspan="1">39 (39.8)</td></tr><tr><td colspan="1" rowspan="1"> Hepatitis C virus</td><td colspan="1" rowspan="1">2 (5.7)</td><td colspan="1" rowspan="1">6 (13.6)</td><td colspan="1" rowspan="1">7 (36.8)</td><td colspan="1" rowspan="1">15 (15.3)</td></tr><tr><td colspan="1" rowspan="1"> Other</td><td colspan="1" rowspan="1">19 (54.3)</td><td colspan="1" rowspan="1">20 (45.5)</td><td colspan="1" rowspan="1">3 (15.8)</td><td colspan="1" rowspan="1">42 (42.9)</td></tr><tr><td colspan="1" rowspan="1"> Missing</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">1 (2.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (2.0)</td></tr></tbody></table><table-wrap-foot><fn><p>ALBI, albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; CP, Child-Pugh; ECOG PS, Eastern Cooperative Oncology Group performance status; Vp4, main portal vein invasion.</p></fn><fn><p>
<sup>a</sup>Due to local regulations, race was not reported for some participants.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Safety</title><sec id="s3-2-1"><title>Treatment Exposure</title><p>The median (interquartile range) number of cycles of durvalumab was 4.0 (2.0–8.0) overall, 2.0 (1.0–5.0) for participants in the CP B7/B8 cohort, 7.0 (4.0–8.5) for participants in the ECOG PS 2 cohort, and 3.0 (1.0–6.0) for participants in the Vp4 cohort. The median (range) total duration of exposure to durvalumab was 3.76 (0.07–13.27) months overall, 1.87 (0.07–10.71) months for participants in the CP B7/B8 cohort, 6.37 (0.92–13.27) months for participants in the ECOG PS 2 cohort, and 2.79 (0.62–10.84) months for participants in the Vp4 cohort.</p></sec><sec id="s3-2-2"><title>Co-Primary Safety Analysis</title><p>At this early safety review, the co-primary endpoint, incidence (95% CI) of grade 3 or 4 PRAEs occurring within 6 months of treatment initiation, was 19.4% (12.1–28.6) overall, 17.1% (6.6–33.6) in the CP B7/B8 cohort, 18.2% (8.2–32.7) in the ECOG PS 2 cohort, and 26.3% (9.1–51.2) in the Vp4 cohort (<xref ref-type="table" rid="T2">Table 2</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Summary of AEs and PRAEs in the safety analysis set</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">
<italic toggle="yes">n</italic> (%)</th><th colspan="1" rowspan="1">CP B7/B8 cohort, <italic toggle="yes">n</italic> = 35</th><th colspan="1" rowspan="1">ECOG PS 2 cohort, <italic toggle="yes">n</italic> = 44</th><th colspan="1" rowspan="1">Vp4 cohort, <italic toggle="yes">n</italic> = 19</th><th colspan="1" rowspan="1">Overall, <italic toggle="yes">N</italic> = 98</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Any CTCAE grade 3 or 4 PRAEs within 6 months of treatment initiation<sup>a, b</sup>, <italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">6 (17.1)</td><td colspan="1" rowspan="1">8 (18.2)</td><td colspan="1" rowspan="1">5 (26.3)</td><td colspan="1" rowspan="1">19 (19.4)</td></tr><tr><td colspan="1" rowspan="1"> 95% CI</td><td colspan="1" rowspan="1">6.6–33.6</td><td colspan="1" rowspan="1">8.2–32.7</td><td colspan="1" rowspan="1">9.1–51.2</td><td colspan="1" rowspan="1">12.1–28.6</td></tr><tr><td colspan="1" rowspan="1">Any AE, <italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">28 (80.0)</td><td colspan="1" rowspan="1">42 (95.5)</td><td colspan="1" rowspan="1">19 (100.0)</td><td colspan="1" rowspan="1">89 (90.8)</td></tr><tr><td colspan="1" rowspan="1"> Any CTCAE grade 3 or 4 AEs<sup>a</sup></td><td colspan="1" rowspan="1">14 (40.0)</td><td colspan="1" rowspan="1">16 (36.4)</td><td colspan="1" rowspan="1">9 (47.4)</td><td colspan="1" rowspan="1">39 (39.8)</td></tr><tr><td colspan="1" rowspan="1"> Any AEs with outcome of death</td><td colspan="1" rowspan="1">2 (5.7)</td><td colspan="1" rowspan="1">3 (6.8)</td><td colspan="1" rowspan="1">4 (21.1)</td><td colspan="1" rowspan="1">9 (9.2)</td></tr><tr><td colspan="1" rowspan="1"> Any AEs leading to discontinuation of any study treatment</td><td colspan="1" rowspan="1">3 (8.6)</td><td colspan="1" rowspan="1">3 (6.8)</td><td colspan="1" rowspan="1">4 (21.1)</td><td colspan="1" rowspan="1">10 (10.2)</td></tr><tr><td colspan="1" rowspan="1"> Any AEs leading to interruption of any study treatment<sup>c</sup></td><td colspan="1" rowspan="1">9 (25.7)</td><td colspan="1" rowspan="1">12 (27.3)</td><td colspan="1" rowspan="1">6 (31.6)</td><td colspan="1" rowspan="1">27 (27.6)</td></tr><tr><td colspan="1" rowspan="1">Any SAEs, <italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">6 (17.1)</td><td colspan="1" rowspan="1">15 (34.1)</td><td colspan="1" rowspan="1">11 (57.9)</td><td colspan="1" rowspan="1">32 (32.7)</td></tr><tr><td colspan="1" rowspan="1"> Any CTCAE grade 3 or 4 SAEs<sup>a</sup></td><td colspan="1" rowspan="1">5 (14.3)</td><td colspan="1" rowspan="1">13 (29.5)</td><td colspan="1" rowspan="1">8 (42.1)</td><td colspan="1" rowspan="1">26 (26.5)</td></tr><tr><td colspan="1" rowspan="1">Any PRAE<sup>b</sup>, <italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">17 (48.6)</td><td colspan="1" rowspan="1">34 (77.3)</td><td colspan="1" rowspan="1">13 (68.4)</td><td colspan="1" rowspan="1">64 (65.3)</td></tr><tr><td colspan="1" rowspan="1"> Any CTCAE grade 3 or 4 PRAEs<sup>a,b</sup></td><td colspan="1" rowspan="1">6 (17.1)</td><td colspan="1" rowspan="1">9 (20.5)</td><td colspan="1" rowspan="1">5 (26.3)</td><td colspan="1" rowspan="1">20 (20.4)</td></tr><tr><td colspan="1" rowspan="1"> Any serious PRAEs<sup>b</sup></td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">8 (18.2)</td><td colspan="1" rowspan="1">5 (26.3)</td><td colspan="1" rowspan="1">14 (14.3)</td></tr><tr><td colspan="1" rowspan="1"> Any CTCAE grade 3 or 4 serious PRAEs<sup>a,b</sup></td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">7 (15.9)</td><td colspan="1" rowspan="1">4 (21.1)</td><td colspan="1" rowspan="1">12 (12.2)</td></tr><tr><td colspan="1" rowspan="1"> Any PRAEs with outcome of death<sup>b</sup></td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (4.5)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (2.0)</td></tr><tr><td colspan="1" rowspan="1">Any imAE<sup>d</sup>, <italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">4 (11.4)</td><td colspan="1" rowspan="1">15 (34.1)</td><td colspan="1" rowspan="1">6 (31.6)</td><td colspan="1" rowspan="1">25 (25.5)</td></tr><tr><td colspan="1" rowspan="1"> imAEs treated with systemic corticosteroids<sup>d</sup></td><td colspan="1" rowspan="1">3 (8.6)</td><td colspan="1" rowspan="1">13 (29.5)</td><td colspan="1" rowspan="1">5 (26.3)</td><td colspan="1" rowspan="1">21 (21.4)</td></tr><tr><td colspan="1" rowspan="1"> imAEs treated with ≥40 mg prednisone equivalent<sup>d</sup></td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">8 (18.2)</td><td colspan="1" rowspan="1">4 (21.1)</td><td colspan="1" rowspan="1">13 (13.3)</td></tr><tr><td colspan="1" rowspan="1">Any AESI, <italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">21 (60.0)</td><td colspan="1" rowspan="1">37 (84.1)</td><td colspan="1" rowspan="1">15 (78.9)</td><td colspan="1" rowspan="1">73 (74.5)</td></tr><tr><td colspan="1" rowspan="1"> AESIs treated with systemic corticosteroids</td><td colspan="1" rowspan="1">5 (14.3)</td><td colspan="1" rowspan="1">13 (29.5)</td><td colspan="1" rowspan="1">5 (26.3)</td><td colspan="1" rowspan="1">23 (23.5)</td></tr><tr><td colspan="1" rowspan="1"> AESIs treated with ≥40 mg prednisone equivalent</td><td colspan="1" rowspan="1">2 (5.7)</td><td colspan="1" rowspan="1">8 (18.2)</td><td colspan="1" rowspan="1">4 (21.1)</td><td colspan="1" rowspan="1">14 (14.3)</td></tr><tr><td colspan="1" rowspan="1">Any infusion reaction AEs, <italic toggle="yes">n</italic> (%)</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">1 (2.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (2.0)</td></tr><tr><td colspan="1" rowspan="1"> Hepatic AEs</td><td colspan="1" rowspan="1">15 (42.9)</td><td colspan="1" rowspan="1">22 (50.0)</td><td colspan="1" rowspan="1">11 (57.9)</td><td colspan="1" rowspan="1">48 (49.0)</td></tr><tr><td colspan="1" rowspan="1"> Hemorrhagic AEs</td><td colspan="1" rowspan="1">3 (8.6)</td><td colspan="1" rowspan="1">6 (13.6)</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">11 (11.2)</td></tr></tbody></table><table-wrap-foot><fn><p>AE, adverse event; AESI, AE of special interest; CI, confidence interval; CP, Child-Pugh; CTCAE, Common Terminology Criteria for Adverse Events; ECOG PS, Eastern Cooperative Oncology Group performance status; imAE, immune-mediate AE; PRAE, adverse event possibly related to study treatment; SAE, serious AE; Vp4, main portal vein invasion.</p></fn><fn><p>
<sup>a</sup>Grade 3: severe, grade 4: life-threatening.</p></fn><fn><p>
<sup>b</sup>As assessed by the investigator. Missing responses are counted as related.</p></fn><fn><p>
<sup>c</sup>AEs on the AE case report form with action taken = drug interrupted.</p></fn><fn><p>
<sup>d</sup>imAEs are identified from AESIs and AEs of possible interest using a programmatic approach.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2-3"><title>Additional Safety Analyses</title><p>Any AEs occurred in 89/98 (90.8%) participants overall and in 28/35 (80.0%), 42/44 (95.5%), and 19/19 (100.0%) participants in the CP B7/B8, ECOG PS 2, and Vp4 cohorts, respectively (<xref ref-type="table" rid="T2">Table 2</xref>). Any SAEs occurred in 32/98 (32.7%) participants overall, and in 6/35 (17.1%), 15/44 (34.1%), and 11/19 (57.9%) participants in the CP B7/B8, ECOG PS 2, and Vp4 cohorts, respectively (<xref ref-type="table" rid="T2">Table 2</xref>). The most common AEs overall were pruritus (26.5%), diarrhea (18.4%), and aspartate aminotransferase increase (16.3%). Other AEs occurring in at least 5% of participants are listed in online supplementary Table 2.</p><p>PRAEs occurred in 64/98 (65.3%) participants overall and in 17/35 (48.6%), 34/44 (77.3%), and 13/19 (68.4%) participants in the CP B7/B8, ECOG PS 2, and Vp4 cohorts, respectively (<xref ref-type="table" rid="T2">Table 2</xref>). Serious PRAEs occurred in 14/98 (14.3%) participants overall and in 1/35 (2.9%), 8/44 (18.2%), and 5/19 (26.3%) participants in the CP B7/B8, ECOG PS 2, and Vp4 cohorts, respectively (<xref ref-type="table" rid="T2">Table 2</xref>). PRAEs leading to death occurred in 2/44 (4.5%) participants in the ECOG PS 2 cohort and were one case each of drug-induced liver injury and blood bilirubin increase. There were no PRAEs, leading to death in the CP B7/B8 or Vp4 cohorts (<xref ref-type="table" rid="T2">Table 2</xref>). The most common PRAEs among all participants were pruritus (20.4%), diarrhea (12.2%), hyperthyroidism (9.2%), and aspartate aminotransferase increase (9.2%; <xref ref-type="table" rid="T3">Table 3</xref>); pruritus was the most common PRAE across cohorts (CP B7/B8 cohort: 14.3% [diarrhea also occurred in 14.3% of participants], ECOG PS 2: 22.7%, and Vp4 cohort: 26.3%; <xref ref-type="table" rid="T3">Table 3</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>PRAEs occurring in ≥5% of participants in the safety analysis set</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">
<italic toggle="yes">n</italic> (%)</th><th colspan="1" rowspan="1">CP B7/B8 cohort, <italic toggle="yes">n</italic> = 35</th><th colspan="1" rowspan="1">ECOG PS 2 cohort, <italic toggle="yes">n</italic> = 44</th><th colspan="1" rowspan="1">Vp4 cohort, <italic toggle="yes">n</italic> = 19</th><th colspan="1" rowspan="1">Overall, <italic toggle="yes">N</italic> = 98</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">Endocrine disorders, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> Hyperthyroidism</td><td colspan="1" rowspan="1">2 (5.7)</td><td colspan="1" rowspan="1">7 (15.9)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">9 (9.2)</td></tr><tr><td colspan="1" rowspan="1"> Hypothyroidism</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">6 (13.6)</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">8 (8.2)</td></tr><tr><td colspan="5" rowspan="1">Gastrointestinal disorders, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> Diarrhea</td><td colspan="1" rowspan="1">5 (14.3)</td><td colspan="1" rowspan="1">3 (6.8)</td><td colspan="1" rowspan="1">4 (21.1)</td><td colspan="1" rowspan="1">12 (12.2)</td></tr><tr><td colspan="5" rowspan="1">Skin and subcutaneous tissue disorders, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> Pruritus</td><td colspan="1" rowspan="1">5 (14.3)</td><td colspan="1" rowspan="1">10 (22.7)</td><td colspan="1" rowspan="1">5 (26.3)</td><td colspan="1" rowspan="1">20 (20.4)</td></tr><tr><td colspan="1" rowspan="1"> Rash</td><td colspan="1" rowspan="1">3 (8.6)</td><td colspan="1" rowspan="1">4 (9.1)</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">8 (8.2)</td></tr><tr><td colspan="1" rowspan="1"> Rash maculo-papular</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">6 (13.6)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">7 (7.1)</td></tr><tr><td colspan="5" rowspan="1">General disorders and administration site conditions, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> Asthenia</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">2 (4.5)</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">5 (5.1)</td></tr><tr><td colspan="5" rowspan="1">Investigations, <italic toggle="yes">n</italic> (%)</td></tr><tr><td colspan="1" rowspan="1"> Alanine aminotransferase increased</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">3 (6.8)</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">5 (5.1)</td></tr><tr><td colspan="1" rowspan="1"> Amylase increased</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">3 (6.8)</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">5 (5.1)</td></tr><tr><td colspan="1" rowspan="1"> Aspartate aminotransferase increased</td><td colspan="1" rowspan="1">3 (8.6)</td><td colspan="1" rowspan="1">4 (9.1)</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">9 (9.2)</td></tr><tr><td colspan="1" rowspan="1"> Blood bilirubin increased</td><td colspan="1" rowspan="1">1 (2.9)</td><td colspan="1" rowspan="1">3 (6.8)</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">5 (5.1)</td></tr><tr><td colspan="1" rowspan="1"> Lipase increased</td><td colspan="1" rowspan="1">2 (5.7)</td><td colspan="1" rowspan="1">3 (6.8)</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">7 (7.1)</td></tr></tbody></table><table-wrap-foot><fn><p>AEs are sorted in international order for system organ class and in alphabetical order for preferred term. Participants with multiple occurrences are counted once per system organ class and preferred term regardless of the number of occurrences. Related to treatment as assessed by the investigator. Missing responses are counted as related.</p></fn><fn><p>CP, Child-Pugh; ECOG PS, Eastern Cooperative Oncology Group performance status; PRAE, adverse event possibly related to study treatment; Vp4, main portal vein invasion.</p></fn></table-wrap-foot></table-wrap><p>imAEs occurred in 25/98 (25.5%) participants overall and in 4/35 (11.4%), 15/44 (34.1%), and 6/19 (31.6%) participants in the CP B7/B8, ECOG PS 2, and Vp4 cohorts, respectively. By data cutoff, 10/25 (40.0%) imAEs were resolved, 14/25 (56.0%) imAEs were unresolved, and 1/25 (4.0%) imAEs resulted in death. The imAE resulting in death occurred in a participant in the ECOG PS 2 cohort and was due to a drug-induced liver injury (the same participant identified as having a PRAE, leading to death above). imAEs leading to treatment with high-dose (≥40 mg prednisone equivalent) glucocorticoids occurred in 13/98 (13.3%) participants overall, 1/35 (2.9%), 8/44 (18.2%), and 4/19 (21.1%) participants in the CP B7/B8, ECOG PS 2, and Vp4 cohorts, respectively (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>Any hemorrhagic AEs occurred in 11/98 (11.2%) participants overall and in 3/35 (8.6%), 6/44 (13.6%), and 2/19 (10.5%) participants in the CP B7/B8, ECOG PS 2, and Vp4 cohorts, respectively, including two participants with gastrointestinal bleeding in the Vp4 cohort and one participant with variceal bleeding in the CP B7/B8 cohort (online suppl. Table 3). While one incident of gastrointestinal hemorrhage in the Vp4 cohort resulted in death, none of the incidents of gastrointestinal or variceal bleeding were considered by the investigator to be related to treatment. Serious hemorrhagic AEs occurred in 4/98 (4.1%) of participants overall.</p></sec></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Early safety data from the SIERRA study demonstrate a manageable safety profile in subgroups of people with uHCC who are often excluded from clinical trials due to their poor prognosis, including participants with more decompensated hepatic function, poorer performance status, or more advanced disease than were included in the HIMALAYA study [<xref ref-type="bibr" rid="B7">7</xref>]. At these data cutoff, the incidence of grade 3 or 4 PRAEs occurring within 6 months of treatment initiation was low overall, though incidence was higher in the Vp4 cohort compared with the other SIERRA cohorts. Overall, the incidence of PRAEs in SIERRA (65.3%) was slightly lower than the incidence of treatment-related AEs reported in the STRIDE arm of the HIMALAYA study (75.8%) [<xref ref-type="bibr" rid="B7">7</xref>]. Additionally, the incidence of SAEs (32.7% overall in SIERRA and 40.5% in the STRIDE arm of HIMALAYA) and grade 3 or 4 AEs (39.8% overall in SIERRA and 50.5% in the STRIDE arm of HIMALAYA) was slightly lower in the SIERRA study compared with the STRIDE arm of the HIMALAYA study [<xref ref-type="bibr" rid="B7">7</xref>]. This is likely due to the shorter median follow-up duration in SIERRA (5.2 months overall in SIERRA and 33.2 months in the STRIDE arm of HIMALAYA) [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The overall incidence of imAEs in SIERRA (25.5%) was lower than what has been reported for the STRIDE arm of the HIMALAYA study (35.8%) [<xref ref-type="bibr" rid="B7">7</xref>]. Furthermore, the incidence of imAEs treated with high-dose glucocorticoids was 13.3% among all participants in the SIERRA study, which is lower than the incidence reported for participants in the HIMALAYA study (20.1% in participants treated with STRIDE). In an analysis of imAEs in the HIMALAYA study, imAEs generally emerged within 3 months of treatment initiation [<xref ref-type="bibr" rid="B24">24</xref>]. This finding aligns well with the broader experience on the emergence of imAEs with immunotherapy [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>]; therefore, it is not expected that the incidence of imAEs will increase significantly with additional follow-up. By the data cutoff, 56% of imAEs remained unresolved; however, the median duration of follow-up in all participants was approximately 5 months; therefore, it is expected that more of these events will resolve with additional follow-up.</p><p>The incidence of any grade hemorrhagic AEs overall in the SIERRA study was low (11.2%), comparable across arms (CP B7/B8 cohort: 8.6%, ECOG PS 2: 13.6%, and Vp4 cohort: 10.5%), and consistent with the incidence reported in the HIMALAYA study (11.3% in the STRIDE arm) [<xref ref-type="bibr" rid="B7">7</xref>]. Furthermore, incidence of serious hemorrhagic AEs was also low among participants in the SIERRA study (4.1% overall). No deaths from hemorrhagic events related to treatment were reported; therefore, despite enrolling participants with a poorer prognosis, the risk of hemorrhage did not appear to be increased compared with participants in the HIMALAYA study [<xref ref-type="bibr" rid="B7">7</xref>]. The low incidence of hemorrhage AEs and the absence of PRAEs leading to death due to hematologic events are particularly important for participants with Vp4, who have an increased risk of experiencing these events. These results are promising considering the higher rates of variceal bleeding events reported in participants with Vp4 who were treated with atezolizumab and bevacizumab versus sorafenib in the IMBrave150 study [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Participants in the Vp4 cohort experienced higher incidence of SAEs, grade 3 or 4 AEs, and AEs that lead to discontinuation or death compared with the other cohorts, though PRAE rates were similar. This is likely reflective of the poor overall prognosis and higher risk for treatment-unrelated AEs for participants with main trunk PVT who were enrolled in this cohort, compared with the other cohorts in the SIERRA study. Therefore, it is expected that they may experience more AEs compared with participants in other cohorts, or versus the HIMALAYA study population [<xref ref-type="bibr" rid="B7">7</xref>]. In the 44 participants from IMbrave150 who had Vp4 and were treated with atezolizumab plus bevacizumab, the rate of grade 3 or 4 treatment-related AEs was 41% and any grade gastrointestinal bleeding events was 23% [<xref ref-type="bibr" rid="B27">27</xref>]. With the STRIDE regimen in the Vp4 cohort of SIERRA, the rate of grade 3 or 4 PRAEs was 26.3% and of hemorrhagic AEs was 10.5%, though sample size was small (<italic toggle="yes">n</italic> = 19) and the duration of follow-up was short. Despite the challenges involved in treating this population, the SIERRA study has demonstrated that safety with STRIDE is manageable for participants with Vp4.</p><p>Despite the expectation that participants with decompensated liver function would have worse outcomes, in SIERRA, the CP B7/B8 cohort had lower rates of any imAEs, any imAEs treated with systemic corticosteroid treatment or ≥40 mg prednisone equivalent, any serious PRAEs and any grade 3 or 4 serious PRAEs than the ECOG PS 2 cohort and Vp4 cohort, which both included only participants with CP A. However, this is likely due to the other confounding prognostic factors for each cohort making the differences in outcomes between participants with CP A and CP B7/B8 in SIERRA difficult to interpret. The ECOG PS 2 cohort had a similar rate of grade 3 or 4 PRAEs within 6 months of treatment initiation as the CP B7/B8 cohort. Rates of grade 3 or 4 PRAEs in the CP B7/B8 cohort were also consistent with rates of grade 3 or 4 TRAEs in participants with CP B7/B8 treated with nivolumab monotherapy in one cohort of the phase 1/2 CheckMate 040 study [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>One of the limitations of the current analysis is that as an early safety review of SIERRA, the duration of follow-up was short compared with the primary analysis of HIMALAYA [<xref ref-type="bibr" rid="B7">7</xref>] and AE rates may increase after longer follow-up. Additionally, efficacy data from the SIERRA study, including the co-primary endpoint of ORR, are still immature at the current data cutoff and will be reported at the subsequent primary analysis. Due to a high screening failure rate in some cohorts, initial recruitment into the CP B7/B8 and Vp4 cohorts was lower than in the ECOG PS 2 cohort, resulting in shorter duration of exposure to durvalumab in the CP B7/B8 and Vp4 cohorts than in the ECOG PS 2 cohort. However, any AEs that occur with additional follow-up will be included in the subsequent primary analysis. A further limitation of SIERRA is that, as in the HIMALAYA study, people with a history of recent gastrointestinal bleeding (within the past 6 months) were excluded to avoid additional risk to individuals with very recent bleeding events [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>To our knowledge, this is the first prospective study investigating the use of combined anti-CTLA-4 and anti-PD-L1 systemic therapies in participants with a poor prognosis. Early safety findings are indicative of a favorable safety profile for STRIDE in this expanded participant population and were consistent with the HIMALAYA study data [<xref ref-type="bibr" rid="B7">7</xref>]. These results support the use of STRIDE in a diverse population of people with uHCC, including those with more decompensated hepatic function, poorer performance status, or more advanced disease, compared with the HIMALAYA study population.</p></sec><sec id="s5" sec-type="acknowledgments"><title>Acknowledgments</title><p>The authors would like to thank the people who volunteered to participate in the SIERRA study, their families and loved ones, all the investigators and study site personnel, and the members of the Independent Data Monitoring Committee. Medical writing support, under the direction of the authors, was provided by Andrea Hough, PhD, CMC Connect, a division of IPG Health Medical Communications, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med. 2022;175(9):1298–1304).</p></sec><sec id="s6" sec-type="statement of ethics"><title>Statement of Ethics</title><p>The SIERRA study was conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation Guideline for Good Clinical Practice, applicable regulatory requirements, and the AstraZeneca Bioethics Policy. The study protocol was approved by Local Institutional Review Boards at each participating center [<xref ref-type="bibr" rid="B28">28</xref>]. Written, informed consent was obtained from participants or their legal representatives before participation.</p></sec><sec id="s7" sec-type="COI-statement"><title>Conflict of Interest Statement</title><p>Stephen Lam Chan reports advisory board fees from AstraZeneca, Eisai, and MSD; being an invited speaker for AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Elevar, IPSEN, MSD, and Roche; and research funding (to institution) from Bayer, Eisai, IPSEN, MSD, and Sirtex Medical. Masatoshi Kudo reports being an invited speaker for Bayer, Chugai Pharma, Eisai, Eli Lilly, MSD, and Takeda; and research funding (to institution) from AbbVie, Chugai Pharma, EA Pharma, Eisai, GE HealthCare, Gilead Sciences, Otsuka, Sumitomo Dainippon Pharma, Taiho, and Takeda. Bruno Sangro reports consulting or advisory fees from AstraZeneca, Bayer, Boston Scientific, Bristol Myers Squibb, Eisai, Ipsen, Roche, Sanofi, and Sirtex Medical; being an invited speaker for AstraZeneca, Eisai, Incyte, Roche, and Sirtex Medical; and research funding (to institution) from Bristol Myers Squibb and Roche. Robin Kate Kelley reports consulting or advisory fees from Agios, AstraZeneca, and MSD (to institution) and from Elevar, GSK, Jazz Pharmaceuticals, J Pharma, Moderna, Regeneron, and Tyra Biosciences (to self); and research funding (to institution) from Agios, AstraZeneca, Bayer, Bristol Myers Squibb, Compass, Eli Lilly, EMD Serono, Exelixis, Genentech, Loxo Oncology, MSD, Novartis, Partner Therapeutics, QED, Relay Therapeutics, Roche, Servier, Surface Oncology, Taiho Pharmaceutical, and Tyra Biosciences. Jee Hyun Kim reports advisory board fees from Daiichi Sankyo Korea, Eisai Co., Ltd, Everest Medicine, Novartis, Pfizer, Roche Korea, and Yuhan; being an invited speaker for Amgen, AstraZeneca, Lilly, Novartis, Roche Diagnostics, and Sanofi-Aventis; and research funding (to institution) from Ono Pharma Korea Co. Ltd. Binh Pham reports no conflicts of interest. Jung Yong Hong reports consulting or advisory fees from AstraZeneca, Elevar Therapeutics, ImmuneOncia, and Roche Korea; being an invited speaker for AstraZeneca, Eisai, Handok, Menarini, MSD, Roche Korea, and Servier. Dirk-Thomas Waldschmidt reports payment for speaker’s bureaus from AstraZeneca, Bayer/Vital, Eisai Germany, Incyte, Ipsen, MSD Oncology, Roche Pharma AG, and Servier; and travel expenses from AstraZeneca, Ipsen, Lilly, and Servier. Donatella Marino reports advisory board fees from AstraZeneca and Merck and travel and meeting expenses from Amgen and AstraZeneca. Jie Xin Joycelyn Lee reports advisory board fees from AstraZeneca, BeiGene, Bristol Myers Squibb, Eisai, Roche, Servier, and Taiho; and research funding (to institution) from Cure51 and Servier. René Gerolami reports travel and meeting expenses from AstraZeneca, Bayer, Gilead, and Roche. Adam M. Burgoyne reports consulting or advisory fees from AstraZeneca, Deciphera, Eisai, Exelixis, Genentech, and Guerbet; and research funding (to institution) from Alnylam, AstraZeneca, Boston Scientific, Cogent, Deciphera, Exelixis, Genentech, Jiangsu Hengrui, Merck, Replimune, Taiho, and Trisalus. Qiao Li is an employee of AstraZeneca. Hitomi Nakamura is an employee of and holds stock in AstraZeneca. Peng Sun is an employee of AstraZeneca. Boris Baur is an employee of and holds stock in AstraZeneca. Lorenza Rimassa reports grant/research funding (to institution) from AbbVie, AstraZeneca, BeiGene, Exelixis, FibroGen, Incyte, Ipsen, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences, and Zymeworks; consulting fees from AbbVie, AstraZeneca, Basilea, Bayer, Bristol Myers Squibb, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, and Zymeworks; honoraria (lecture fees) from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Guerbet, Incyte, Ipsen, Roche, and Servier; and travel expenses from AstraZeneca and Servier. Lorenza Rimassa is Associate Editor for Liver Cancer.</p></sec><sec id="s8" sec-type="funding sources"><title>Funding Sources</title><p>This study was funded by AstraZeneca. AstraZeneca sponsored the trial, provided the trial drugs, and collaborated with the Steering Committee on the trial design and data collection, analysis, and interpretation. The manuscript was prepared and approved by all authors, with medical writing support funded by the sponsor. The sponsor reviewed and approved for submission the final draft of the manuscript to ensure accuracy of references to AstraZeneca products and clinical studies, guard against disclosure of confidential information, and check that information relevant to pending patents was handled appropriately.</p></sec><sec id="s9" sec-type="author contributions"><title>Author Contributions</title><p>Conception and design of the study: B.B., L.R., S.L.C., B.S., R.K.K., H.N., and P.S.; data acquisition: J.H.K., D.M., R.G., L.R., A.M.B., S.L.C., and M.K.; analysis and interpretation of data: R.G., A.M.B., Q.L., J.X.J.L., B.B., L.R., S.L.C., B.S., R.K.K., H.N., M.K., P.S., BP, J.Y.H., and D.-T.W.; study supervision: Q.L., L.R., S.L.C., B.S., R.K.K., H.N., M.K., and P.S.; writing and reviewing: R.G., A.M.B., Q.L., J.X.J.L., B.B., L.R., S.L.C., B.S., R.K.K., H.N., M.K., J.H.K., D.M., P.S., B.P., J.Y.H., and D.-T.W.</p></sec></body><back><sec id="s16" sec-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are not publicly available to fulfill legal and ethical obligations to protect the data from misuse. Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at <ext-link ext-link-type="uri" xlink:href="https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure" xmlns:xlink="http://www.w3.org/1999/xlink">https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ext-link>. Data for studies not listed on Vivli can be requested through Vivli at <ext-link ext-link-type="uri" xlink:href="https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/" xmlns:xlink="http://www.w3.org/1999/xlink">https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/</ext-link>. The request will undergo an internal review process, and if approved, data will be prepared and shared with specified accessors named on the request form for 12 months via Vivli Secure Research Environment. AstraZeneca Vivli member page is also available outlining further details: <ext-link ext-link-type="uri" xlink:href="https://vivli.org/ourmember/astrazeneca/" xmlns:xlink="http://www.w3.org/1999/xlink">https://vivli.org/ourmember/astrazeneca/</ext-link>.</p></sec><sec id="s24" sec-type="supplementary-material"><label>Supplementary Material</label><supplementary-material content-type="local-data" id="SD1" orientation="portrait" position="float"><media id="d67e1827" orientation="portrait" position="anchor" xlink:href="Supplementary_material-Suppl.1-s1.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Bray</surname>
<given-names>F</given-names>
</string-name>, <string-name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sung</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></string-name>, <etal/></person-group>. <article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>. <year>2024</year>;<volume>74</volume>(<issue>3</issue>):<fpage>229</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">38572751</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3322/caac.21834</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<collab>European Association for the Study of the Liver</collab>
</person-group>. <article-title>EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma</article-title>. <source>J Hepatol</source>. <year>2025</year>;<volume>82</volume>(<issue>2</issue>):<fpage>315</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">39690085</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2024.08.028</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>National Comprehensive Cancer Network</collab>
</person-group>. <article-title>NCCN Clinical Practice Guidelines in oncology (NCCN guidelines<sup>®</sup>)</article-title>. In: <source>Hepatocellular carcinoma</source>; <year>2025</year>. Version 1.2025.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Vogel</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Kelley</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Llovet</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source>. <year>2025</year>;<volume>36</volume>(<issue>5</issue>):<fpage>491</fpage>–<lpage>506</lpage>.<pub-id pub-id-type="pmid">39986353</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.annonc.2025.02.006</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Singal</surname>
<given-names>AG</given-names>
</string-name>, <string-name name-style="western"><surname>Llovet</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Yarchoan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Heimbach</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>LA</given-names></string-name>, <etal/></person-group>. <article-title>AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma</article-title>. <source>Hepatology</source>. <year>2023</year>;<volume>78</volume>(<issue>6</issue>):<fpage>1922</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">37199193</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/HEP.0000000000000466</pub-id><pub-id pub-id-type="pmcid">PMC10663390</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Finn</surname>
<given-names>RS</given-names>
</string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ikeda</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Galle</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Ducreux</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>TY</given-names></string-name>, <etal/></person-group>. <article-title>Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>20</issue>):<fpage>1894</fpage>–<lpage>905</lpage>.<pub-id pub-id-type="pmid">32402160</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJMoa1915745</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Abou-Alfa</surname>
<given-names>GK</given-names>
</string-name>, <string-name name-style="western"><surname>Lau</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kudo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Kelley</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Furuse</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma</article-title>. <source>NEJM Evid</source>. <year>2022</year>;<volume>1</volume>(<issue>8</issue>):<fpage>EVIDoa2100070</fpage>.<pub-id pub-id-type="pmid">38319892</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/EVIDoa2100070</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Cheng</surname>
<given-names>A-L</given-names>
</string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ikeda</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Galle</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Ducreux</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>T-Y</given-names></string-name>, <etal/></person-group>. <article-title>Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma</article-title>. <source>J Hepatol</source>. <year>2022</year>;<volume>76</volume>(<issue>4</issue>):<fpage>862</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">34902530</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2021.11.030</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Qin</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study</article-title>. <source>Lancet</source>. <year>2023</year>;<volume>402</volume>(<issue>10408</issue>):<fpage>1133</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">37499670</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(23)00961-3</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Yau</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western"><surname>Galle</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Decaens</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sangro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>da Fonseca</surname><given-names>LG</given-names></string-name>, <etal/></person-group>. <article-title>Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial</article-title>. <source>Lancet</source>. <year>2025</year>;<volume>405</volume>(<issue>10492</issue>):<fpage>1851</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">40349714</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(25)00403-9</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Rimassa</surname>
<given-names>L</given-names>
</string-name>, <string-name name-style="western"><surname>Personeni</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Czauderna</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Foerster</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Galle</surname><given-names>P</given-names></string-name></person-group>. <article-title>Systemic treatment of HCC in special populations</article-title>. <source>J Hepatol</source>. <year>2021</year>;<volume>74</volume>(<issue>4</issue>):<fpage>931</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">33248171</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2020.11.026</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Sangro</surname>
<given-names>B</given-names>
</string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Kelley</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Lau</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kudo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sukeepaisarnjaroen</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma</article-title>. <source>Ann Oncol</source>. <year>2024</year>;<volume>35</volume>(<issue>5</issue>):<fpage>448</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">38382875</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.annonc.2024.02.005</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Rimassa</surname>
<given-names>L</given-names>
</string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Sangro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lau</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kudo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Reig</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC</article-title>. <source>J Hepatol</source>. <year>2025</year>;<volume>83</volume>(<issue>4</issue>):<fpage>899</fpage>–<lpage>908</lpage>.<pub-id pub-id-type="pmid">40222621</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2025.03.033</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>AstraZeneca [Internet]</collab>
</person-group>. <source>Imfinzi plus imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers</source>. [cited 2023 Aug 15]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-approved-in-japan-for-3-cancers.html" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-approved-in-japan-for-3-cancers.html</ext-link></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>Administration TFaD</collab>
</person-group>. <source>IMJUDO assessment report</source>. <year>20232025</year>. Available from:.<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f638339377980908900&amp;type=2&amp;cid=45601" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f638339377980908900&amp;type=2&amp;cid=45601</ext-link></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>AstraZeneca [Internet]</collab>
</person-group>. <source>Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers</source>. [cited 2023 May 9]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers.html" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers.html</ext-link></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>DailyPharmKorea [Internet]</collab>
</person-group>. <source>Imfinzi+Imjudo combo approved for liver cancer in KOR</source>. [cited 2025 Jul 7]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.dailypharmkorea.com/Users/News/NewsView.html?ID=4757" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.dailypharmkorea.com/Users/News/NewsView.html?ID=4757</ext-link></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>European Medicines Agency [Internet]</collab>
</person-group>. <source>Imfinzi (durvalumab): summary of product characteristics</source>. [cited 2025 Jun 17]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf</ext-link></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>European Medicines Agency [Internet]</collab>
</person-group>. <source>Imjudo (tremelimumab): summary of product characteristics</source>. [cited 2023 Aug 15]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf</ext-link></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>US Food and Drug Administration [Internet]</collab>
</person-group>. <source>Imfinzi (durvalumab): highlights of prescribing information [cited 2025 Jun 17]</source>. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s035lbl.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s035lbl.pdf</ext-link></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Kudo</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western"><surname>Matilla</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Santoro</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Melero</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gracián</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Acosta-Rivera</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis</article-title>. <source>J Hepatol</source>. <year>2021</year>;<volume>75</volume>(<issue>3</issue>):<fpage>600</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">34051329</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2021.04.047</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Chauhan</surname>
<given-names>AF-KM</given-names>
</string-name>, <string-name name-style="western"><surname>Farid-Kapadia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Goel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Valerio</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Vaidya</surname><given-names>N</given-names></string-name></person-group>. <article-title>Characterization of the real-world first line (1L) use of single dose tremelimumab regular interval durvalumab (STRIDE), for treatment of Unresectable Hepatocellular Carcinoma (uHCC), using two Electronic Medical Record (EMR) databases</article-title>. <source>J Clin Oncol</source>. <year>2025</year>;<volume>43</volume>(<issue>4_Suppl l</issue>):<fpage>534</fpage>.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Fujii</surname>
<given-names>Y</given-names>
</string-name>, <string-name name-style="western"><surname>Kawaoka</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shirane</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Miura</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Nakahara</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yamaoka</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>First-line durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in real-world clinical practice</article-title>. <source>Oncology</source>. <year>2025</year>;<volume>103</volume>(<issue>8</issue>):<fpage>742</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">39527933</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1159/000542517</pub-id><pub-id pub-id-type="pmcid">PMC12324697</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Lau</surname>
<given-names>G</given-names>
</string-name>, <string-name name-style="western"><surname>Sangro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Kudo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kelley</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Tak</surname><given-names>WY</given-names></string-name>, <etal/></person-group>. <article-title>Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial</article-title>. <source>Hepatology</source>. <year>2025</year>.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/HEP.0000000000001385</pub-id><pub-id pub-id-type="pmid">40384092</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Fukushima</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western"><surname>Morimoto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kobayashi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ueno</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Uojima</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hidaka</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Association between immune-related adverse events and survival in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab</article-title>. <source>Oncologist</source>. <year>2023</year>;<volume>28</volume>(<issue>7</issue>):<fpage>e526</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">37023703</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/oncolo/oyad090</pub-id><pub-id pub-id-type="pmcid">PMC10322131</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Breder</surname>
<given-names>VV</given-names>
</string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Merle</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Finn</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Galle</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>AX</given-names></string-name>, <etal/></person-group>. <article-title>IMbrave150: exploratory efficacy and safety results of Hepatocellular Carcinoma (HCC) Patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study</article-title>. <source>J Clin Oncol</source>. <year>2021</year>;<volume>39</volume>(<issue>15_Suppl l</issue>):<fpage>4073</fpage>.34724392
</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Finn</surname>
<given-names>RS</given-names>
</string-name>, <string-name name-style="western"><surname>Galle</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Ducreux</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Reilly</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nicholas</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Efficacy and safety of atezolizumab plus Bevacizumab versus Sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in IMbrave150</article-title>. <source>Liver Cancer</source>. <year>2024</year>;<volume>13</volume>(<issue>6</issue>):<fpage>655</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">39687036</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1159/000539897</pub-id><pub-id pub-id-type="pmcid">PMC11649257</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="book">
<person-group person-group-type="author">
<collab>ClinicalTrials.gov [Internet]</collab>
</person-group>. <source>Durvalumab and tremelimumab as first line treatment in participants with advanced hepatocellular carcinoma (HCC) (SIERRA)</source>. [cited 2025 June 19]. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05883644?term=NCT05883644&amp;rank=1#study-overview" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/study/NCT05883644?term=NCT05883644&amp;rank=1#study-overview</ext-link></mixed-citation></ref></ref-list></back></article>